Scienza e Tecnologia
YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies
"We are on the cusp of a breakthrough in individualized cancer treatments" said Dr. Wolfgang Fischl , Chief Executive Officer of YGION. "This financing is truly exciting for YGION as we see it as a strong validation of our unique approach, and we are grateful for the support of our investors enabling us to take a significant step towards clinical validation of our technology. With the continued demonstration of the efficacy of our approach, we are open to additional investors and collaborators interested in our ground-breaking approach."
"We are confident that with our technology, we can realize the promise of simple, safe and effective cancer vaccines" added Dr. Geert Mudde , Chief Technology Officer of YGION. "Our YGNITE platform gives us the unique ability to identify, select and synthesise relevant neoantigens, and combined with our CARGONAUT immune-modulating carrier induces a powerful cell-mediated tumor specific response that targets and eliminates malignant cells with unmatched safety."
YGION's lead program YG-01 is currently in preclinical development.
Sophie Zettl Ph.D.
Chief Business Officer, YGION Biomedical GmbH
sophie.zettl@ygion.bio
+43 660 573 1746
View original content: https://www.prnewswire.co.uk/news-releases/ygion-biomedical-announces-15-million-series-a-financing-to-develop-individualized-cancer-immunotherapies-302149015.html